SCOOP: Tylenol Maker Privately Admitted Evidence Was Getting ‘Heavy’ For Autism Risk In 20181/3(sorry about all the red text but this has made me more angry, then many things we research)
The pharmaceutical company behind Tylenol privately acknowledged thelikelihood of an association between its drug in pregnancy and neurodevelopmental disorders like autism in children seven years ago, company documents obtained by the Daily Caller News Foundation show.
“The weight of the evidence is starting to feel heavy to me,” said Rachel Weinstein, U.S. director of epidemiology for Janssen, the pharmaceutical arm of Johnson & Johnson, in 2018. Johnson & Johnson marketed Tylenol at the timebut in 2023 spun off its consumer products division into a separate company called Kenvue.
Legacy media headlines and vocal public health experts have dismissed the conclusion of President Donald Trump and Health and Human Services(HHS) Secretary Robert F. Kennedy Jr. that Tylenol taken in pregnancy and early infancy has driven rises in autism.But one stakeholder has for years viewed the evidence as credible enough to act upon, at least privately: The makers of Tylenol.
The DCNF obtained the company documents from the law firm Keller Postman LLC, which brought a class action lawsuit against Kenvue in the Federal District Court for the Southern District of New York.
To be sure, much of the highly-cited researchon autism spectrum disorder emphasizes genetic rather than environmental drivers.The scientific community continues to debate its causes, with many scientists agreeing that multiple factors may be at play.
The company’s FAQ webpage says that “acetaminophen is an active ingredient in all TYLENOL® products andin more than 600 other over-the-counter (OTC) and prescription medicines.”
A decade before Weinstein’s email, in 2008, Johnson & Johnson began receiving queriesfrom consumers and physicians about a possible link, emails show.
“Not much choice but to consider this a safety signal that needs to be evaluated,” J&J Office of Consumer Medical Safety Lead Andre Mann wrote in 2008 after receiving a letter from a physician with concerns.
Leslie Shur, the head of the division of Johnson & Johnson that monitors the side effects of drugs already on the market, received an alert in 2012 about concerns about acetaminophen and autism from a concerned father, with one employee writing “in case this goes to press.”
Concerns about a link between Tylenol andneurological disorders may have reached the C-suite by 2014, according to another email, which references then-Johnson & Johnson CEO Alex Gorski.
The makers of Tylenol have closely tracked a drumbeat of scientific publications finding an association between taking the blockbuster drug in pregnancy and infancy and autism risk, other company documents show.
A 2018 internal presentation the company labeled “privileged and confidential” acknowledgesthat observational studies showa “somewhat consistent” association between prenatal exposure to Tylenoland neurodevelopmental disorders. Another presentation slide acknowledges that larger meta-analyses — reviews summarizing multiple scientific studies — found an association, but notes weaknesses of these studies like confounding variables and subjectivity in measuring autistic traits.
“Johnson & Johnson divested its consumer health business years ago, and all rights and liabilities associated with the sale of its over-the-counter products, including Tylenol (acetaminophen), are owned by Kenvue,” a Johnson & Johnson spokesman said in a statement.
https://dailycallernewsfoundation.org/2025/09/26/scoop-tylenol-maker-privately-admitted-evidence-was-getting-heavy-for-autism-risk-in-2018/